Moore Capital Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-104,333
Closed -$3.26M – 800
2025
Q4
$3.26M Sell
104,333
-60,864
-37% -$1.5M 0.05% 309
2025
Q3
$3.34M Buy
+165,197
New +$2.9M 0.05% 299
2020
Q2
– Sell
-1,100,000
Closed -$9.88M – 295
2020
Q1
$9.88M Buy
+1,100,000
New +$11.3M 0.41% 59
2016
Q1
– Sell
-31,994
Closed -$2.1M – 337
2015
Q4
$2.1M Buy
+31,994
New +$1.98M 0.07% 211
2015
Q1
– Sell
-180,000
Closed -$10.4M – 464
2014
Q4
$10.4M Buy
+180,000
New +$10M 0.33% 85

Other funds holding TEVA

Moore Capital Management's TEVA Position: Q1 2026 in Review

Moore Capital Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q1 2026, closing a stake of 104,333 shares — an estimated $3.26M sold.

Moore Capital Management first reported a position in TEVA in Q4 2014 and held it in 5 quarters. The position peaked at $10.4M in Q4 2014. 653 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Moore Capital Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q1 2026 after selling out during the quarter.
  • Moore Capital Management sold 104,333 Teva Pharmaceutical Industries Limited shares in Q1 2026, an estimated $3.26M.
  • Moore Capital Management first reported a position in Teva Pharmaceutical Industries Limited in Q4 2014 and held it in 5 quarters.
  • Moore Capital Management's Teva Pharmaceutical Industries Limited position peaked at $10.4M in Q4 2014.
  • 653 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.